SRD5A1
3-oxo-5-alpha-steroid 4-dehydrogenase 1
Also known as: S5A1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P18405
- Gene
- SRD5A1
- Ensembl
- ENSG00000145545
- Chromosome
- 5
- Canonical length
- 259 aa
- Protein class
- Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins
OverviewNCBI Gene
Steroid 5-alpha-reductase (EC 1.3.99.5) catalyzes the conversion of testosterone into the more potent androgen, dihydrotestosterone (DHT). Also see SRD5A2 (MIM 607306).[supplied by OMIM, Mar 2008]
Canonical amino-acid sequenceUniProt
259 residues, UniProt reviewed canonical sequence.
>P18405|SRD5A1
1 MATATGVAEE RLLAALAYLQ CAVGCAVFAR NRQTNSVYGR HALPSHRLRV PARAAWVVQE
61 LPSLALPLYQ YASESAPRLR SAPNCILLAM FLVHYGHRCL IYPFLMRGGK PMPLLACTMA
121 IMFCTCNGYL QSRYLSHCAV YADDWVTDPR FLIGFGLWLT GMLINIHSDH ILRNLRKPGD
181 TGYKIPRGGL FEYVTAANYF GEIMEWCGYA LASWSVQGAA FAFFTFCFLS GRAKEHHEWY
241 LRKFEEYPKF RKIIIPFLFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SRD5A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 5
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 27 nTPM
Expression across tissuesHPA
Tissue
- liver: 27 nTPM
- skin: 13 nTPM
- esophagus: 11 nTPM
- breast: 10 nTPM
- cerebral cortex: 7 nTPM
- vagina: 6.5 nTPM
Single-cell type
- esophageal basal cells: 186 nCPM
- hepatocytes: 170 nCPM
- esophageal suprabasal cells: 163 nCPM
- suprabasal keratinocytes: 117 nCPM
- basal keratinocytes: 82 nCPM
- distal convoluted tubule cells: 60 nCPM
Immune cell
- basophil: 3.4 nTPM
- myeloid DC: 1.6 nTPM
- classical monocyte: 1.3 nTPM
- non-classical monocyte: 1.1 nTPM
- intermediate monocyte: 1 nTPM
- plasmacytoid DC: 0.7 nTPM
Brain region
- cerebral cortex: 38 nTPM
- white matter: 37 nTPM
- cerebellum: 36 nTPM
- thalamus: 36 nTPM
- pons: 35 nTPM
- medulla oblongata: 33 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.29
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.59
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- androgen biosynthetic process
- androgen catabolic process
- bone development
- cell differentiation
- cellular response to cAMP
- cellular response to dexamethasone stimulus
- cellular response to epinephrine stimulus
- cellular response to estradiol stimulus
- cellular response to growth factor stimulus
- cellular response to insulin stimulus
- cellular response to serotonin
- cellular response to starvation
- cellular response to testosterone stimulus
- cerebral cortex development
- diterpenoid metabolic process
- female genitalia development
- hippocampus development
- hypothalamus development
- liver development
- male genitalia development
- male gonad development
- pituitary gland development
- progesterone metabolic process
- response to estrogen
- response to follicle-stimulating hormone
- response to fungicide
- response to growth hormone
- response to muscle activity
- response to resveratrol
- response to xenobiotic stimulus
- serotonin metabolic process
- sex determination
- spinal cord development
- thalamus development
- urogenital system development
Molecular functions
- 3-oxo-5-alpha-steroid 4-dehydrogenase (NADP+) activity
- 3-oxo-5-alpha-steroid 4-dehydrogenase activity
- amide binding
- electron transfer activity
- NADPH binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SRD5A1 as an antibody target. Whether an autoantibody or antibody against SRD5A1 could matter depends on whether native SRD5A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SRD5A1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SRD5A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...